Central nervous system diseaseXx_NEWLINE_xXPatients must not have clinical evidence of central nervous system involvement by lymphoma; if performed, any laboratory or radiographic tests performed to assess central nervous system (CNS) involvement must be negativeXx_NEWLINE_xXMedically apparent central nervous system lymphoma or leptomeningeal diseaseXx_NEWLINE_xXUntreated or active central nervous system metastasesXx_NEWLINE_xXKnown central nervous system involvement by PTCLXx_NEWLINE_xXPatients with known symptomatic central nervous system metastases requiring steroids.Xx_NEWLINE_xXCentral nervous system lymphoma or leptomeningeal infiltrationXx_NEWLINE_xXHistory of central nervous system lymphoma (either primary or metastatic).Xx_NEWLINE_xXClinical evidence of active central nervous system leukemia;Xx_NEWLINE_xXParticipant must not have a known uncontrolled malignancy of the central nervous system.Xx_NEWLINE_xXPatients with evidence of current central nervous system leukemic involvementXx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXSymptomatic and/or untreated central nervous system metastasesXx_NEWLINE_xXSymptomatic central nervous system metastasesXx_NEWLINE_xXPresence of active/uncontrolled central nervous system involvementXx_NEWLINE_xXPatients with any central nervous system involvement or CTCL.Xx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXActive central nervous system metastasesXx_NEWLINE_xXKnown central nervous system lymphoma.Xx_NEWLINE_xXHistory of central nervous system metastasisXx_NEWLINE_xXKnown central nervous system mass lesionXx_NEWLINE_xXHas a history of primary central nervous system malignancy.Xx_NEWLINE_xXParticipants with known untreated brain or other central nervous system metastases are excludedXx_NEWLINE_xXCentral nervous system metastasesXx_NEWLINE_xXHave known central nervous system malignancy or metastasis.Xx_NEWLINE_xXHistory of seizure disorders or unstable central nervous system metastasesXx_NEWLINE_xXCentral nervous system involvement by lymphoma, including leptomeningeal involvementXx_NEWLINE_xXPatient with a tumor metastasis in the central nervous systemXx_NEWLINE_xXPatients with untreated central nervous system metastasesXx_NEWLINE_xXKnown central nervous system metastasesXx_NEWLINE_xXKnown central nervous system lymphomaXx_NEWLINE_xXSymptomatic and/or untreated central nervous system metastasesXx_NEWLINE_xXEXCLUSION - INFUSION: Patients with central nervous system involvementXx_NEWLINE_xXCentral nervous system malignancyXx_NEWLINE_xXMyeloma-related central nervous system involvementXx_NEWLINE_xXHave symptomatic central nervous system malignancy or metastasis.Xx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXCentral nervous system involvement with lymphoma at any time in the patientâ€™s history; intrathecal prophylaxis during induction is allowed as long as active disease has not been identifiedXx_NEWLINE_xXSuggestive central nervous system involvement with leukemiaXx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXSymptomatic central nervous system involvement.Xx_NEWLINE_xXMetastatic disease to the central nervous systemXx_NEWLINE_xXCentral nervous system involvement.Xx_NEWLINE_xXKnown central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)Xx_NEWLINE_xXPatients with known central nervous system metastases, including lymphomatous meningitisXx_NEWLINE_xXCentral nervous system metastases, including lymphomatous meningitisXx_NEWLINE_xXAny active central nervous system or meningeal involvementXx_NEWLINE_xXWithout clinical signs of active central nervous system diseaseXx_NEWLINE_xXKnown central nervous system or visceral metastasesXx_NEWLINE_xXDiagnosis of primary central nervous system lymphomaXx_NEWLINE_xXEvidence of lymphoma outside of the central nervous system\r\n* Ocular involvement will not excludeXx_NEWLINE_xXKnown central nervous system involvementXx_NEWLINE_xXKnown, current central nervous system disease involvement or untreated brain metastasesXx_NEWLINE_xXDocumented central nervous system metastases or liver metastasisXx_NEWLINE_xXKnown active involvement of the central nervous system by lymphoma or leukemiaXx_NEWLINE_xXPrimary central nervous system malignancyXx_NEWLINE_xXKnown central nervous system malignancy. Note: Central nervous system imaging is only required in subjects with suspected central nervous system malignancy.Xx_NEWLINE_xXActive central nervous system metastases and/or leptomeningeal diseaseXx_NEWLINE_xXSymptomatic central nervous system metastasesXx_NEWLINE_xXUncontrolled central nervous system metastasesXx_NEWLINE_xXPatients/subjects with suspected or known central nervous system metastases unless adequately treatedXx_NEWLINE_xXSubjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvementXx_NEWLINE_xXPresence of symptomatic or uncontrolled central nervous system or leptomeningeal metastasesXx_NEWLINE_xXHas either clinical evidence of or history of central nervous system involvement by AML.Xx_NEWLINE_xXHistory of central nervous system lymphoma (either primary or metastatic).Xx_NEWLINE_xXActive or previous central nervous system leukemia involvementXx_NEWLINE_xXCentral nervous system involvement with disease under study (myeloma), or concurrent AL amyloidosis or plasma cell leukemiaXx_NEWLINE_xXPatients who have known central nervous system involvement with multiple myeloma will be excluded from this clinical trialXx_NEWLINE_xXActive or previous central nervous system leukemia involvementXx_NEWLINE_xXCentral nervous system lymphoma, including lymphomatous meningitisXx_NEWLINE_xXCentral nervous system involvement with MM (by clinical symptoms and signs).Xx_NEWLINE_xXHave known central nervous system malignancy or metastasis.Xx_NEWLINE_xXHistory of central nervous system lymphoma (either primary or metastatic).Xx_NEWLINE_xXActive involvement of the central nervous system with malignancyXx_NEWLINE_xXNo known history or suspicion of central nervous system involvement by lymphomaXx_NEWLINE_xXPatient has known active central nervous system metastases.Xx_NEWLINE_xXUntreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune diseaseXx_NEWLINE_xXMust not have suspected or known central nervous system metastases unless adequately treatedXx_NEWLINE_xXUntreated or progressive central nervous system leukemiaXx_NEWLINE_xXActive central nervous system malignancyXx_NEWLINE_xXSubjects must not have known central nervous system involvement by disease (parenchymal, meningeal or cerebrospinal fluid)Xx_NEWLINE_xXCentral nervous system metastases, including leptomeningeal involvementXx_NEWLINE_xXRapidly progressive, clinically unstable central nervous system hematological malignancy. Note: Central nervous system evaluation is only required in subjects with known or suspected central nervous system malignancy.Xx_NEWLINE_xXKnown central nervous system involvement with the disease under studyXx_NEWLINE_xXPersons with uncontrolled central nervous system malignancyXx_NEWLINE_xXPatients with active central nervous system leukemia or requiring maintenance intrathecal chemotherapyXx_NEWLINE_xXPrimary central nervous system involvement onlyXx_NEWLINE_xXPatients with known central nervous system involvement should be excluded from this clinical trialXx_NEWLINE_xXKnown central nervous system lymphomaXx_NEWLINE_xXActive central nervous system malignancyXx_NEWLINE_xXHas known active central nervous system involvement of the malignancy.Xx_NEWLINE_xXPatients with known or suspected central nervous system involvement of lymphoma.Xx_NEWLINE_xXAll patients with central nervous system involvement with lymphomaXx_NEWLINE_xXKnown lymphomatous involvement of the central nervous systemXx_NEWLINE_xXHistory of central nervous system multiple myeloma involvementXx_NEWLINE_xXActive meningeal or central nervous system diseaseXx_NEWLINE_xXSuspected AML-related central nervous system involvement; a lumbar puncture (LP) is not required to exclude central nervous system (CNS) diseaseXx_NEWLINE_xXSubjects with known central nervous system involvement with multiple myelomaXx_NEWLINE_xXActive involvement of the central nervous system with malignancyXx_NEWLINE_xXPresence of any central nervous system tumor that has not been stable for at least 4 weeks off corticosteroids.Xx_NEWLINE_xXSymptomatic untreated metastases in the central nervous systemXx_NEWLINE_xXAND (by central assessment) either:Xx_NEWLINE_xXActive central nervous system leukemiaXx_NEWLINE_xXKnown active central nervous system lymphomaXx_NEWLINE_xXActive central nervous system lymphomaXx_NEWLINE_xXAll patients with central nervous system lymphomaXx_NEWLINE_xXKnown active central nervous system involvementXx_NEWLINE_xXDocumented central nervous system metastases or liver metastasisXx_NEWLINE_xXCentral nervous system involvement of the disease under studyXx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXKnown lymphomatous involvement of the central nervous systemXx_NEWLINE_xXKnown central nervous system involvementXx_NEWLINE_xXClinically active central nervous system leukemia.Xx_NEWLINE_xXPresence of central nervous system involvement of leukemia or a history of primary central nervous system leukemia.Xx_NEWLINE_xXPrevious radiotherapy for central nervous system metastasesXx_NEWLINE_xXPatients with evidence of active central nervous system lymphomaXx_NEWLINE_xXKnown central nervous system lymphomaXx_NEWLINE_xXPatients must not have active central nervous system involvementXx_NEWLINE_xXPrimary central nervous system lymphoma or known intracranial involvementXx_NEWLINE_xXKnown central nervous system metastasis. Patients with history of central nervous system metastases are eligible if they are clinically or radiographically stable for at least 3 months and not taking steroids or anticonvulsants.Xx_NEWLINE_xXPatients with known malignant disease of the central nervous system.Xx_NEWLINE_xXNewly diagnosed MCL: Central nervous system lymphomaXx_NEWLINE_xXSubjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvementXx_NEWLINE_xXPatient has a primary central nervous system tumorXx_NEWLINE_xXActive central nervous system lymphomaXx_NEWLINE_xXKnown central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)Xx_NEWLINE_xXAny history of disease involving the central nervous system (Part 1). Known active disease involving the central nervous system (Part 2).Xx_NEWLINE_xXPresence of untreated or symptomatic central nervous system metastases, or central nervous system metastases that currently require local therapy (such as radiotherapy or surgery), or require doses of corticosteroids within the prior 4 weeksXx_NEWLINE_xXActive central nervous system tumor or metastasesXx_NEWLINE_xXKnown active central nervous system or leptomeningeal lymphomaXx_NEWLINE_xXCentral nervous system or meningeal involvementXx_NEWLINE_xXActive involvement of the central nervous system with malignancyXx_NEWLINE_xXActive involvement of the central nervous system with malignancyXx_NEWLINE_xXActive central nervous system malignancyXx_NEWLINE_xXActive central nervous system malignancyXx_NEWLINE_xXPatients may have active malignancy outside the central nervous systemXx_NEWLINE_xXKnown central nervous system brain metastasesXx_NEWLINE_xXSymptomatic central nervous system metastasesXx_NEWLINE_xXActive, untreated central nervous system metastases.Xx_NEWLINE_xXActive central nervous system malignancyXx_NEWLINE_xXCentral nervous system involvement.Xx_NEWLINE_xXKnown metastasis to the central nervous systemXx_NEWLINE_xXKnown metastasis or symptoms of metastasis to the central nervous systemXx_NEWLINE_xXActive central nervous system involvement with AML.Xx_NEWLINE_xXKnown central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)Xx_NEWLINE_xXKnown active involvement of the central nervous system by lymphoma or leukemiaXx_NEWLINE_xXKnown central nervous system leukemiaXx_NEWLINE_xXKnown central nervous system involvement by multiple myelomaXx_NEWLINE_xXPatients with known central nervous system involvement should be excluded from this clinical trialXx_NEWLINE_xXCentral nervous system involvement (Bing-Neel syndrome)Xx_NEWLINE_xXKnown involvement of central nervous systemXx_NEWLINE_xXPRE-REGISTRATION: Primary tumors of the central nervous system.Xx_NEWLINE_xXCentral nervous system involvement by lymphoma, including leptomeningeal involvementXx_NEWLINE_xXPatients should not have evidence of active central nervous system lymphomaXx_NEWLINE_xXAll patients with central nervous system lymphoma.Xx_NEWLINE_xXPatients with known central nervous system infiltration with leukemiaXx_NEWLINE_xXClinical evidence of central nervous system involvement.Xx_NEWLINE_xXKnown central nervous system involvement or brain metastasesXx_NEWLINE_xXActive central nervous system involvement by leukemiaXx_NEWLINE_xXActive central nervous system involvementXx_NEWLINE_xXKnown central nervous system metastasesXx_NEWLINE_xXPatients with a history of central nervous system involvement by CLL or who have prolymphocytic leukemia (PLL)Xx_NEWLINE_xXPatients with documented central nervous system involvement of AMLXx_NEWLINE_xXUncontrolled central nervous system metastasesXx_NEWLINE_xXActive central nervous system involvement by malignancyXx_NEWLINE_xXDocumented current central nervous system involvement by multiple myelomaXx_NEWLINE_xXLymphoma involving the central nervous systemXx_NEWLINE_xXCentral nervous system disease as evidence by clinical symptomatologyXx_NEWLINE_xXLymphoma involving the central nervous systemXx_NEWLINE_xXExhibiting clinical signs of or has a known history of meningeal or central nervous system involvement by multiple myelomaXx_NEWLINE_xXSubject has clinically active central nervous system leukemia.Xx_NEWLINE_xXHistory of or current, central nervous system involvement with AML.Xx_NEWLINE_xXSubjects with known central nervous system diseaseXx_NEWLINE_xXActive, untreated central nervous system metastases.Xx_NEWLINE_xXKnown clinically active central nervous system involvement.Xx_NEWLINE_xXSubject has known active central nervous system involvement with AML.Xx_NEWLINE_xXPatient must have no prior history or current clinically apparent central nervous system metastasesXx_NEWLINE_xXKnown central nervous system metastases or central nervous system as the only source of diseaseXx_NEWLINE_xXActive central nervous system disease.Xx_NEWLINE_xXKnown central nervous system metastases or central nervous system as the only source of diseaseXx_NEWLINE_xXPatients with controlled asymptomatic central nervous system involvement are allowed.Xx_NEWLINE_xXUncontrolled central nervous system metastasesXx_NEWLINE_xXKnown history of central nervous system metastasisXx_NEWLINE_xXKnown active central nervous system or leptomeningeal lymphomaXx_NEWLINE_xXParticipants with known central nervous system diseaseXx_NEWLINE_xXHas known active central nervous system metastasesXx_NEWLINE_xXCentral nervous system involvement with lymphoma, including parenchymal and leptomeningeal diseaseXx_NEWLINE_xXCentral nervous system metastasisXx_NEWLINE_xXCurrent or past history of central nervous system lymphomaXx_NEWLINE_xXKnown brain or central nervous system metastases or history of uncontrolled seizures.Xx_NEWLINE_xXHas a history of known central nervous system metastasisXx_NEWLINE_xXCentral nervous system lymphoma or leptomeningeal infiltrationXx_NEWLINE_xXKnown central nervous system lymphomaXx_NEWLINE_xXSymptomatic central nervous system metastases (excluding Glioblastoma multiforrme (GBM) and Primary Central Nervous System Lymphoma (PCNSL). Subjects with brain metastases that have been previously treated and are stable for 6 weeks are allowed.Xx_NEWLINE_xXSubjects with active central nervous system metastasesXx_NEWLINE_xXKnown active central nervous system lymphoma or leptomeningeal diseaseXx_NEWLINE_xXKnown or suspected central nervous system metastasesXx_NEWLINE_xXSubjects with Central Nervous System involvement with multiple myelomaXx_NEWLINE_xXCentral nervous system lymphoma or leptomeningeal infiltrationXx_NEWLINE_xXCentral nervous system involvement of the CLLXx_NEWLINE_xXHave confirmed presence of central nervous system metastasesXx_NEWLINE_xXPatients with known central nervous system metastases.Xx_NEWLINE_xXActive uncontrolled central nervous system involvementXx_NEWLINE_xXUntreated or symptomatic central nervous system metastases.Xx_NEWLINE_xXPresence or history of central nervous system involvement by lymphoma.Xx_NEWLINE_xXLymphoma involving the central nervous systemXx_NEWLINE_xXHistory of central nervous system metastasis.Xx_NEWLINE_xXPatients with known central nervous system involvement at the time of study entry will be excluded from this clinical trialXx_NEWLINE_xXSymptomatic and/or untreated central nervous system metastasesXx_NEWLINE_xXCentral nervous system metastasesXx_NEWLINE_xXKnown central nervous system lymphoma (either primary or metastatic).Xx_NEWLINE_xXSubject has clinically active central nervous system leukemia.Xx_NEWLINE_xXKnown, current central nervous system disease involvement or untreated brain metastasesXx_NEWLINE_xXPatients with known central nervous system, meningeal, or epidural disease.Xx_NEWLINE_xXPrimary or secondary Central Nervous System involvement by lymphoma.Xx_NEWLINE_xXMyeloma-related central nervous system involvementXx_NEWLINE_xXPatients with leukemic involvement of the central nervous systemXx_NEWLINE_xXHave clinical evidence or history of central nervous system metastasis.Xx_NEWLINE_xXCentral nervous system involvement (based on clinical assessment)Xx_NEWLINE_xXCurrent central nervous systemic diseaseXx_NEWLINE_xXPresence of known central nervous system or brain metastasesXx_NEWLINE_xXKnown central nervous system lymphoma or leptomeningeal disease, except subjects with a history of central nervous system lymphoma treated and in remission > 6 monthsXx_NEWLINE_xXKnown clinically active central nervous system involvementXx_NEWLINE_xXKnown active involvement of the central nervous system by lymphoma or leukemiaXx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXSubjects with active cancer that has spread to the central nervous systemXx_NEWLINE_xXKnown lymphomatous involvement of the central nervous system.Xx_NEWLINE_xXKnown central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)Xx_NEWLINE_xXAll patients with central nervous system lymphomaXx_NEWLINE_xXActive central nervous system involvement by lymphomaXx_NEWLINE_xXKnown central nervous system involvementXx_NEWLINE_xXUntreated central nervous system metastatic disease lXx_NEWLINE_xXCentral nervous system involvement.Xx_NEWLINE_xXKnown involvement of the central nervous system by WM.Xx_NEWLINE_xXPresence of symptomatic or uncontrolled brain or central nervous system metastasesXx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXHave clinical evidence or history of central nervous system metastasisXx_NEWLINE_xXPatients with a history of central nervous system involvement by lymphomaXx_NEWLINE_xXKnown central nervous system lymphomaXx_NEWLINE_xXPatient has central nervous system leukemiaXx_NEWLINE_xXNewly diagnosed or uncontrolled cancer-related central nervous system diseaseXx_NEWLINE_xXActive involvement of the central nervous system with malignancyXx_NEWLINE_xXKnown central nervous system lymphomaXx_NEWLINE_xXSubject has clinically active central nervous system leukemia.Xx_NEWLINE_xXAsymptomatic, central nervous system metastases are permittedXx_NEWLINE_xXClinical evidence of active central nervous system leukemia at the time of screeningXx_NEWLINE_xXPresence of confirmed distant metastases, including central nervous system and vertebral or meningeal involvementXx_NEWLINE_xXCentral nervous system disease involvementXx_NEWLINE_xXKnown central nervous system or primary mediastinal lymphomaXx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXKnown Central nervous system involvement, brain metastasisXx_NEWLINE_xXKnown central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required); patients with human T-cell lymphotropic virus type 1 (HTLV1) adult T-cell leukemia/lymphoma (ATLL) and controlled central nervous system (CNS) or meningeal involvement may be enrolled after discussion with the Memorial Sloan Kettering (MSK) principal investigatorXx_NEWLINE_xXAll patients with history of central nervous system lymphomaXx_NEWLINE_xXKnown active central nervous system involvementXx_NEWLINE_xXHave malignancy or metastasis of the central nervous systemXx_NEWLINE_xXKnown central nervous system leukemia/lymphoma or Richter's transformationXx_NEWLINE_xXCentral nervous system involvement.Xx_NEWLINE_xXPresence or history of central nervous system metastasis (including brain)Xx_NEWLINE_xXPresence or history of central nervous system involvement by lymphomaXx_NEWLINE_xXCentral nervous system function defined as not severely somnolent or comatose (central cortical neurotoxicity scale < grade 3)Xx_NEWLINE_xXKnown central nervous system involvement by leukemiaXx_NEWLINE_xXHistory of demyelinating disease or inflammatory disease of the central nervous system or the peripheral nervous systemXx_NEWLINE_xXPatients with primary central nervous system tumors or brain metastases.Xx_NEWLINE_xXHas active or untreated brain or central nervous system metastases.Xx_NEWLINE_xXNo known central nervous system involvement by myeloma.Xx_NEWLINE_xXHistory of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.Xx_NEWLINE_xXActive or history of central nervous system metastases.Xx_NEWLINE_xXMedically apparent central nervous system lymphoma or leptomeningeal diseaseXx_NEWLINE_xXCentral nervous system lymphoma or leptomeningeal diseaseXx_NEWLINE_xXDisease-related central nervous system involvementXx_NEWLINE_xXKnown central nervous system metastasisXx_NEWLINE_xXDocumented current central nervous system involvement by leukemia or lymphomaXx_NEWLINE_xXActive central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)Xx_NEWLINE_xXCLL central nervous system involvementXx_NEWLINE_xXHistory or clinically suspicious for cancer-related Central Nervous System diseaseXx_NEWLINE_xXPatient have uncontrolled brain metastases or central nervous system disease.Xx_NEWLINE_xXPatients may have active malignancy outside the central nervous systemXx_NEWLINE_xXActive central nervous system metastasesXx_NEWLINE_xXNo known involvement of central nervous system by lymphomaXx_NEWLINE_xXKnown central nervous system lymphomaXx_NEWLINE_xXEvidence of sanctuary site involvement by disease, e.g., central nervous system, ocular, testicular involvementXx_NEWLINE_xXKnown central nervous system malignancy.Xx_NEWLINE_xXKnown central nervous system lymphoma or ALL with central nervous system (CNS) involvementXx_NEWLINE_xXPrevious central nervous system leukemiaXx_NEWLINE_xXActive involvement of the central nervous system with malignancyXx_NEWLINE_xXKnown central nervous system metastasis that is unstable within the last 2 monthsXx_NEWLINE_xXHistory of lymphoma involving the central nervous systemXx_NEWLINE_xXKnown central nervous system metastasesXx_NEWLINE_xXUntreated central nervous system involvementXx_NEWLINE_xXActive, untreated central nervous system metastases.Xx_NEWLINE_xXActive, untreated central nervous system metastases.Xx_NEWLINE_xXKnown central nervous system involvementXx_NEWLINE_xXKnown central nervous system involvementXx_NEWLINE_xXActive central nervous system involvement by malignancy; central nervous system disease that has been treated into remission is permitted; a chart note of the clinicianâ€™s impression of lack of central nervous system (CNS) involvement is acceptableXx_NEWLINE_xXKnown or suspected brain or central nervous system metastasesXx_NEWLINE_xXKnown active leukemia of the central nervous systemXx_NEWLINE_xXAll patients with active central nervous system lymphomaXx_NEWLINE_xXKnown central nervous system metastasesXx_NEWLINE_xXCentral nervous system injury or severe neurological impairmentXx_NEWLINE_xXSymptomatic central nervous system metastases or lesions requiring treatment.Xx_NEWLINE_xXCentral nervous system metastasisXx_NEWLINE_xXDocumented current central nervous system involvementXx_NEWLINE_xXCentral nervous system metastasesXx_NEWLINE_xXPresence of clinically apparent untreated central nervous system metastases.Xx_NEWLINE_xXUntreated central nervous system metastasesXx_NEWLINE_xXSymptomatic central nervous system involvementXx_NEWLINE_xXPatients with known central nervous system metastasis are not eligibleXx_NEWLINE_xXSymptomatic central nervous system disease, malignancy, or metastasisXx_NEWLINE_xXKnown uncontrolled central nervous system involvementXx_NEWLINE_xXPrimary brain or other central nervous system malignancy.Xx_NEWLINE_xXLymphoma involvement of the central nervous systemXx_NEWLINE_xXHistory of central nervous system hemorrhageXx_NEWLINE_xXMedically apparent central nervous system lymphoma or leptomeningeal diseaseXx_NEWLINE_xXCentral nervous system or leptomeningeal lymphomaXx_NEWLINE_xXKnown presence of central nervous system metastasesXx_NEWLINE_xXEvidence of central nervous system metastasisXx_NEWLINE_xXCentral nervous system metastasesXx_NEWLINE_xXFor Part B only: Known leukemic involvement or clinical symptoms of leukemic involvement of the central nervous systemXx_NEWLINE_xXAny history or signs of central nervous system metastases;Xx_NEWLINE_xXSevere central nervous system, pulmonary, or renal disease not related to the participant's cancer.Xx_NEWLINE_xXSymptomatic and/or untreated central nervous system metastasesXx_NEWLINE_xXHas a history of primary central nervous system malignancy.Xx_NEWLINE_xXPatient has no worsening central nervous system symptoms; andXx_NEWLINE_xXSubject has clinically active central nervous system leukemiaXx_NEWLINE_xXUntreated central nervous system metastasesXx_NEWLINE_xXEvidence of central nervous system lymphoma or lymphomatous meningitisXx_NEWLINE_xXKnown central nervous system disease (e.g., Alzheimer's disease).Xx_NEWLINE_xXPatients with central nervous system diseaseXx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXPatients with a history of central nervous system involvement by lymphomaXx_NEWLINE_xXPatients with known central nervous system involvement.Xx_NEWLINE_xXPatients must not have clinical evidence of central nervous system involvement by lymphoma, since proposed treatment would not be able to address it adequately; any laboratory (e.g., lactate dehydrogenase [LDH]) or radiographic tests performed to access central nervous system (CNS) involvement must be negative and must be performed within 42 days prior to registrationXx_NEWLINE_xXKnown, active (symptomatic) involvement of the central nervous system by leukemia.Xx_NEWLINE_xXUntreated or active brain metastases or central nervous system cancer, as defined per protocolXx_NEWLINE_xXActive central nervous system tumors or metastasesXx_NEWLINE_xXKnown leukemic involvement of the central nervous system.Xx_NEWLINE_xXHistory or presence of known central nervous system metastasesXx_NEWLINE_xXDocumented current central nervous system involvement by leukemia or lymphomaXx_NEWLINE_xXCentral nervous system involvementXx_NEWLINE_xXKnown central nervous system metastasisXx_NEWLINE_xXHas central nervous system involvementXx_NEWLINE_xXSubjects with known central nervous system metastases.Xx_NEWLINE_xXSymptomatic central nervous system malignancy or metastasis (screening not required).Xx_NEWLINE_xXPrimary malignancy of the central nervous system.Xx_NEWLINE_xXUncontrolled central nervous system metastasesXx_NEWLINE_xXCentral nervous system tumors are allowedXx_NEWLINE_xXKnown central nervous system metastasisXx_NEWLINE_xXKnown central nervous system lymphomaXx_NEWLINE_xXMetastatic disease to the central nervous systemXx_NEWLINE_xXHistory of central nervous system involvement of lymphoma;Xx_NEWLINE_xXActive MM involving the central nervous system.Xx_NEWLINE_xXAll patients with active central nervous system involvement with lymphomaXx_NEWLINE_xXActive central nervous system lesionsXx_NEWLINE_xXKnown and untreated, or active central nervous system metastasesXx_NEWLINE_xXKnown central nervous system metastases or central nervous system as the only source of diseaseXx_NEWLINE_xXKnown or suspected brain or other central nervous system metastasesXx_NEWLINE_xXPresence of symptomatic central nervous system metastases.Xx_NEWLINE_xXHave known central nervous system metastasis or Central Nervous System lymphoma;Xx_NEWLINE_xXOvert central nervous system manifestations of leukemia at diagnosisXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: No central nervous system involvement of diseaseXx_NEWLINE_xXPatients with active central nervous system involvementXx_NEWLINE_xXActive central nervous system malignancyXx_NEWLINE_xXSymptomatic, untreated or unstable central nervous system or leptomeningeal metastasesXx_NEWLINE_xXSymptomatic central nervous system involvement.Xx_NEWLINE_xXHistory of central nervous system involvement or symptoms suggestive of central nervous system involvement by multiple myelomaXx_NEWLINE_xXKnown metastases to the central nervous systemXx_NEWLINE_xXKnown central nervous system involvement by multiple myelomaXx_NEWLINE_xXSubjects with known central nervous system diseaseXx_NEWLINE_xXActive, untreated central nervous system metastases.Xx_NEWLINE_xXHistory or current evidence of central nervous system lymphomaXx_NEWLINE_xXMM involving the central nervous system.Xx_NEWLINE_xXSubject has clinically active central nervous system leukemia.Xx_NEWLINE_xXDiagnosis: Must have MRI documenting a measurable lesion w/in central nervous system consistent with primary central nervous system tumor, for which maximal safe surgical resection is indicatedXx_NEWLINE_xXHistory of primary central nervous system lymphoma or neoplastic central nervous system diseaseXx_NEWLINE_xXKnown uncontrolled central nervous system involvement by malignant diseaseXx_NEWLINE_xX